SEC-sourced researchBeta

TRDA

Entrada Therapeutics, Inc.

US markets

Data passport

CIK: 0001689375
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 10, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 3:03 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

TRDA · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2024	210,782,000.0000	Feb 26, 2026
December 2025	25,421,000.0000	Feb 26, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	25,421,000.0000	-143,750,000.0000	-128,512,000.0000	377,378,000.0000	71,245,000.0000	Feb 26, 2026
December 2024	210,782,000.0000	65,626,000.0000	-41,557,000.0000	526,321,000.0000	97,643,000.0000	Feb 26, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$25.42M	December 2025	Feb 26, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$210.78M	December 2024	Feb 26, 2026	10-K
Net incomeNetIncomeLoss	-$143.75M	December 2025	Feb 26, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$128.51M	December 2025	Feb 26, 2026	10-K
Total assetsAssets	$377.38M	December 2025	Feb 26, 2026	10-K
Total liabilitiesLiabilities	$71.25M	December 2025	Feb 26, 2026	10-K

New filings

Explore methodology ↗